Dr. Traylor is a published scientist and has served as a Medical and Clinical Affairs professional for nineteen years. She earned her PhD in Pharmacology and Toxicology from the University of Arkansas for Medical Sciences. Following her post-doctoral fellowship at Duke University in 1997, she began her career with Miltenyi Biotec, a Bay Area based biologics/devices Company, in a regulatory and clinical affairs role, where she quickly advanced to a leadership position. Dr. Traylor played a pivotal role in developing a forward thinking clinical and regulatory strategy for Miltenyi’s magnetic cell purification platform, ultimately creating broad access to the technology for the advancement of cell-based therapy research.
Since then, Dr. Traylor has held multiple Clinical Development and Medical Affairs leadership positions for international biotech and pharmaceutical companies, including Abbott Laboratories, Amylin Pharmaceuticals, The Binding Site and Novartis Oncology. Prior to joining Biodesix, she launched three first-in-class products in the renal, diabetes and oncology therapeutic areas and supported all phases of clinical development and commercialization of the products. During her seven-year tenure at The Binding Site, she and her team were instrumental in developing a thought leader strategy to support market development for a novel diagnostic biomarker that challenged the long held standard of care. Their flagship immunology based biomarker, which Dr. Traylor also supported, was not only a required test for the diagnosis of myeloma, the test was established as one of three key factors in a Mayo Clinic developed risk stratification model for monitoring pre-malignant and high-risk patients that became widely adopted during her tenure at the company.
Since joining Biodesix in 2015, Dr. Traylor has been leading the Medical Affairs strategy to collaborate with key thought leaders from major academic institutions to drive the awareness of their paradigm shifting proteomic classifier development platform that will ultimately set a new standard for the use diagnostic biomarkers in clinical practice. Since joining the company’s Executive Team, she has revitalized the Clinical Development strategy and led her team in demonstrating the capacity of both genomic and proteomic biomarkers, and the importance of multivariate biomarkers, to redefine precision medicine for the benefit of patients.
Dr. Traylor is an active volunteer for the MSL Society, as a lecturer and mentor, paying it forward to current and future medical affairs professionals who want a rewarding and challenging career that significantly impacts the lives of patients.